This site is intended only for healthcare professionals resident in the Republic of Ireland
The efficacy and safety of XELJANZ for the treatment of adult patients with moderately to severely active ulcerative colitis was demonstrated in three Phase III randomised, double-blind, placebo controlled trials (RCTs): OCTAVE Induction 1 and 2, and OCTAVE Sustain1
*Final complete efficacy assessment at Week 8/52
BID= twice daily, LTE= long-term extension
In the OCTAVE Phase III studies, outcomes were measured for disease activity, health-related quality of life and health utility using multiple endpoints1,3:
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
In the OCTAVE UC trials, remission was defined more stringently than in previous clinical trials for UC, by including the requirement of a rectal bleeding subscore of 0.3
Learn more about the XELJANZ safety profile
Learn about dosing in UC
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023